Market Overview:
The global idiopathic pulmonary fibrosis treatment market reached a value of US$ 3,278 Million in 2021. Looking forward, IMARC Group expects the market to reachUS$ 5,268 Million by 2027, exhibiting at a CAGR of 7.89%during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Idiopathic pulmonary fibrosis (IPF) refers to a progressive and irreversible fibrosing interstitial pneumonia that directly impacts the functioning of the lungs. It is characterized by the formation of scar tissue within the lungs that starts at the edges and progresses toward the center, thus causing difficulties in breathing and insufficient delivery of oxygen to the body parts. It is diagnosed through chest imaging studies, lung biopsies, pulmonary function tests and antibody tests. Two of the most commonly used antifibrotic therapy includes nintedanib and pirfenidone-based drugs, which improves lung functioning and minimizes the risks of acute respiratory deterioration. They are often coupled with oxygen therapy and palliative care to provide comfort and improve the recovery of the patient.
The increasing prevalence of fibrotic diseases, along with the rising geriatric population across the globe, is one of the key factors driving the growth of the market. Furthermore, changing lifestyle patterns and increasing consumption of nicotine products, such as cigarettes, is providing a thrust to the market growth. Moreover, smoking tobacco and cigarettes is considered as one of the most common causes for the development of IPF. In line with this, increasing health consciousness among the masses regarding the effective management strategies of IPF is also favoring the growth of the market. Additionally, the advent of novel medicines and advancements in the IPF diagnostic and treatment methods, are acting as other growth-inducing factors. This, along with extensive research and development (R&D) activities and improvements in the healthcare infrastructure, represents some of the other factors anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global idiopathic pulmonary fibrosis treatment market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug class and end user.
Breakup by Drug Class:
- MAPK Inhibitors
- Tyrosine Inhibitors
- Autotaxin Inhibitors
Breakup by End User:
- Hospitals
- Long-term Care Facilities
- Others
Breakup by Region:
- North America
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being AdAlta Pty Ltd., Angion Biomedica Corp., Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche AG (Roche Holding AG), Fibrogen Inc., Galapagos NV, Liminal BioSciences Inc., Medicinova Inc., Merck & Co. Inc., Novartis AG and Vectura Group Plc.
Report Coverage:
| Report Features |
Details |
| Base Year of the Analysis |
2021 |
| Historical Period |
2016-2021 |
| Forecast Period |
2022 - 2027 |
| Units |
US$ Million |
| Segment Coverage |
Drug Class,End User, Region |
| Region Covered |
亚太地区、欧洲、北美、拉丁美洲, Middle East and Africa |
| Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered |
AdAlta Pty Ltd., Angion Biomedica Corp., Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche AG (Roche Holding AG), Fibrogen Inc., Galapagos NV, Liminal BioSciences Inc., Medicinova Inc., Merck & Co. Inc., Novartis AG and Vectura Group Plc. |
| Customization Scope |
10% Free Customization |
| Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
| Post-Sale Analyst Support |
10-12 Weeks |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global idiopathic pulmonary fibrosis treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global idiopathic pulmonary fibrosis treatment market and who are the key players?
- 行业的竞争程度是什么?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Idiopathic Pulmonary Fibrosis Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 MAPK Inhibitors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Tyrosine Inhibitors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Autotaxin Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by End User
7.1 Hospitals
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Long-term Care Facilities
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2Asia Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1市场趋势
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 AdAlta Pty Ltd.
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.2 Angion Biomedica Corp.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.3 Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG)
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.4 Bristol-Myers Squibb Company
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 Cipla Inc.
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 Financials
13.3.5.4 SWOT Analysis
13.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 SWOT Analysis
13.3.7 Fibrogen Inc.
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.8 Galapagos NV
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.9 Liminal BioSciences Inc.
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3金融类股
13.3.10 Medicinova Inc.
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.10.3 Financials
13.3.10.4 SWOT Analysis
13.3.11 Merck & Co. Inc.
13.3.11.1 Company Overview
13.3.11.2 Product Portfolio
13.3.11.3 Financials
13.3.11.4 SWOT Analysis
13.3.12 Novartis AG
13.3.12.1 Company Overview
13.3.12.2 Product Portfolio
13.3.12.3 Financials
13.3.12.4 SWOT Analysis
13.3.13 Vectura Group Plc
13.3.13.1 Company Overview
13.3.13.2 Product Portfolio
13.3.13.3 Financials
13.3.13.4 SWOT Analysis
List of Figures
Figure 1: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Major Drivers and Challenges
Figure 2: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016-2021
Figure 3: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2021
Figure 4: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2021
Figure 5: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Region (in %), 2021
Figure 6: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 7: Global: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 8: Global: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 9: Global: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: North America: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: North America: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: United States: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Canada: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
图24:加拿大:特发性肺纤维化Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: China: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: China: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: India: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: India: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: South Korea: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: South Korea: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Australia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Australia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: Europe: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
图42:欧洲:特发性Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: Germany: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: Germany: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: France: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: France: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: United Kingdom: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: United Kingdom: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: Italy: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: Italy: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: Spain: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: Spain: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: Russia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: Russia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: Latin America: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: Latin America: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: Brazil: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: Brazil: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: Mexico: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: Mexico: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Middle East and Africa: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Middle East and Africa: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: SWOT Analysis
Figure 68: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: Value Chain Analysis
Figure 69: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (in Million US$), 2022-2027
Table 3: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by End User (in Million US$), 2022-2027
Table 4: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 5: Global: Idiopathic Pulmonary Fibrosis Treatment Market Structure
Table 6: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Key Players